Lypanosys is a drug development company developing a clinically differentiated drug for the rapidly growing and under-served Dermatology market.

Lypanosys' initial drug compound, LYP-010 is formulated as an oral systemic drug for the treatment of atopic dermatitis.

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease of childhood and a not uncommon condition in adults. In the US alone there are >30 million AD sufferers.

Due to its chronic, unrelenting nature, AD can be associated with profound morbidity. Signs and symptoms that are hallmarks of this skin condition often have significant negative impact on the affected individual's physical, social, emotional, and even financial status, leading to a significant decrease in the quality of life, not only of the patient, but also of the patient's family. Current treatments generally offer temporary relief, require cumbersome and messy applications, or are associated with toxicity significant enough to make them unacceptable for use in many younger populations, or for use in those who require repeated or long-term treatment.

In particular, many of the current therapies are not options for use in infants or children, the population with the greatest disease prevalence. Therefore, there is a growing public health need for new AD treatments that are not only effective but also that are safer and can be used longer-term in both children and adults.

LYP-010 is currently being trialed in AD sufferers under an Investigational New Drug (IND) application filed with the US Food and Drug Administration.

There are several other potential indications for Lypanosys' technology but by focusing on the AD market, Lypanosys will minimize drug development risk and reduce development times. LYP-010 has several distinct advantages that will differentiate it from other competitive offerings. Current treatments are largely based on topical products (steroid and immunosuppressant creams or ointments). These products are onerous and inconvenient to apply when patients have more than a small body surface area affected and there are safety concerns about prolonged use. This provides LYP-010 a strong competitive advantage being a safe, systemically acting, orally administered compound.